Unsupervised clustering of SARS-CoV-2 positive hospitalized patients identifies six endophenotypes of COVID-19 and points to FGFR and SHC4-signaling in acute respiratory distress syndrome

William Ma^{1,*}, Antoine Soulé^{1,*}, Katelyn Liu², Catherine Allard³, Karine Tremblay^{4, †}, Simon

Rousseau^{2, +}, and Amin Emad^{1, 5, +}

^{*} These authors contributed equally.

¹ Department of Electrical and Computer Engineering, McGill University, Montréal, QC, Canada

² The Meakins-Christie Laboratories at the Research Institute of the McGill University Heath Centre Research Institute, & Department of Medicine, Faculty of Medicine, McGill University, Montréal, QC, Canada

³ Statistical department, Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS), Sherbrooke, Canada.

⁴ Pharmacology-physiology Department, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Saguenay, QC, Canada; Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, QC, Canada; CRCHUS, Sherbrooke, Canada.

⁵ Mila, Quebec Al Institute, Montréal, QC, Canada

⁺ Corresponding Authors:
Amin Emad,
755 McConnell Engineering Building, 3480 University Street, Montreal H3A 0E9, Canada Email: amin.emad@mcgill.ca

Simon Rousseau, RI-MUHC, E M3.2244, 1001 Décarie, Montréal H4A 3J1, Canada, Email: simon.rousseau@mcgill.ca

Karine Tremblay, Pavillon des Augustines, local AUG-5-01A, 225 St-Vallier street, Chicoutimi G7H 7P2, Canada Email: karine.tremblay@usherbrooke.ca

1 Abstract

2 Defining the molecular mechanisms of novel emerging diseases like COVID-19 is crucial to identify 3 treatable traits to improve patient care. To circumvent a priori bias and the lack of in-depth 4 knowledge of a new disease, we opted for an unsupervised approach, using the detailed 5 circulating proteome, as measured by 4985 aptamers (SOMAmers), of 731 SARS-CoV-2 PCR-6 positive hospitalized participants to Biobanque québécoise de la COVID-19 (BQC19). The 7 consensus clustering identified six endophenotypes (EPs) present in this cohort, with varying 8 degrees of disease severity. One endophenotype, EP6, was associated with a greater proportion 9 of ICU admission, mechanical ventilation, acute respiratory distress syndrome (ARDS) and death. 10 Clinical features of this endophenotype, showed increased levels of C-reactive protein, D-dimers, 11 elevated neutrophils, and depleted lymphocytes. Moreover, metabolomic analysis supported a 12 role for immunothrombosis in severe COVID-19 ARDS. Furthermore, the approach enabled the 13 identification of Fibroblast Growth Factor Receptor (FGFR) and SH2-containing transforming 14 protein 4 (SHC4) signaling as features of the molecular pathways associated with severe COVID-15 19. Finally, this information was sufficient to train an accurate predictive model solely based on 16 clinical laboratory measurements, suggesting the use of blood markers as surrogates for 17 generalizing these EPs to new patients and automating identification of high-risk groups in the 18 clinic.

19 Introduction

20 The coronavirus disease 2019 (COVID-19) is a new human disease caused by the coronavirus 21 SARS-CoV-2 infection that has been assessed pandemic by the World Health Organization in 22 March 2020. As SARS-CoV-2 infection spread, a breath of outcomes of the infection became 23 apparent, from asymptomatic individuals to severely ill and dying, from complete recovery to long-lasting symptoms^{1,2}. The emergence of novel diseases such as COVID-19 presents the 24 25 medical and scientific community with numerous challenges. Among them, defining the 26 molecular mechanisms of disease related to specific outcomes is important to identify treatable 27 traits and improve the performance of healthcare systems facing the challenges brought by the 28 pandemic.

29

30 Successfully reaching this precision medicine goal requires a more granular definition of the 31 pathology. A symptom-based method to discover molecular mechanisms of the disease may 32 result in a challenge emerging from the fact that the same higher-level phenomenon, such as 33 COVID-19 severity, can be produced by several different molecular mechanisms, a phenomenon termed the «many-one» limitation³. Recent advances in computing strategies, such as machine 34 35 learning, has enabled the development of methods that help overcome this limitation by starting 36 from molecular profiles instead of symptoms to define endophenotypes, *i.e.* subgroups of 37 individuals who are inapparent to traditional methods but share a common set of molecular factors that can lead to treatable traits⁴. Establishing successful treatment strategies requires a 38 39 tailored approach to the underlying molecular mechanisms that can help predict and alter 40 disease trajectories⁵. Endophenotypes can become apparent using extensive molecular

41 phenotyping combined with machine learning algorithms⁶⁻⁸. Current investigations of 42 endophenotypes in COVID-19 have mainly relied on supervised approaches using fixed outcomes 43 (such as disease severity) and integrating clinical variables at the onset⁹. We hypothesize that 44 using an unsupervised approach exploiting a rich molecular dataset can provide novel 45 mechanistic insights into the pathobiology of severe COVID-19 that can help physicians improve 46 diagnosis and prognosis.

47

Therefore, this study aims to identify endophenotypes linked to diverse clinical trajectories of COVID-19 using the extensive molecular phenotyping of a cohort of 731 SARS-CoV-2 positive hospitalized patients from the *Biobanque québécoise de la COVID-19* (BQC19, www.quebeccovidbiobank.ca)¹⁰, a prospective observational cohort of SARS-CoV-2 positive and negative participants recruited in the province of Québec, Canada, to improve our understanding of COVID-19 pathobiology and our capacity to alter disease outcomes.

54

In this manuscript, we report the identification of six endophenotypes in hospitalized SARS-CoV-2 positive participants to BQC19, associated with different clinical trajectories. The molecular information underpinning these endophenotypes were used to increase our understanding of pathobiology and predict the likelihood of patients admitted to the hospital to belong to each endophenotype using clinical blood workups.

60

61

63 Results

64 Unsupervised clustering of SARS-CoV-2-positive hospitalized BQC19 participants reveal 65 endophenotypes associated with varying disease severity

In this study, we aimed to identify endophenotypes of COVID-19 based on the circulating 66 67 proteome of patients in our cohort of SARS-CoV-2 positive hospitalized participants to BQC19 (n 68 = 1,362, Table 1), using an unsupervised approach. Figure S1 shows the distribution of the time of hospital admission of the patients and the corresponding waves as defined by National 69 Institute of Public Health of Quebec (https://www.inspq.qc.ca/covid-19). For this purpose, we 70 71 performed consensus agglomerative clustering of the subset of patients (n = 731, Table S1) for whom data corresponding to circulating proteome measured by a multiplex SOMAmer affinity 72 array (Somalogic, ~5,000 aptamers)¹¹ was available in BQC19. The remaining samples were kept 73 74 aside for follow-up analysis. First, the optimal number of clusters (k = 6) was identified using two 75 criteria, Akaike's Information Criteria (AIC) and Bayesian Information Criteria (BIC) (Figure 1A); then, consensus agglomerative clustering (Euclidean distance and Ward linkage)^{12,13} using 76 77 bootstrap subsampling was performed to obtain six robust clusters (see Methods for details) 78 (Figure 1, Figures S2 and S3).

79

The clinical and pathological characteristics of patients in each endophenotype is provided in Table S1. To characterize the identified endophenotypes (EPs) with respect to disease severity, we performed two-sided Fisher's exact test to assess their enrichment (or depletion) in "severe" or "dead" outcome. EP6 was significantly enriched in the severe/dead outcomes (Benjamini-Hochberg false discovery rate (FDR) = 1.72E-18) with these outcomes observed in 66.1% of EP6

85 patients. Meanwhile, EP1 was significantly depleted in severe/dead outcomes (FDR = 8.23E-11) 86 (Figure 2A, Table S1) with these outcomes only observed in 11.6% of EP1 patients. In addition, 87 EP6 was enriched in participants 1) receiving oxygen therapy (FDR = 6.24E-12), 2) receiving 88 ventilatory support (FDR = 6.63E-12), and 3) being admitted to intensive care unit (ICU) (FDR= 1.26E-22) (Figure 2A, Table S1). Kaplan Meier analysis¹⁴ also confirmed that the identified EPs 89 90 have a distinct temporal pattern of admission to ICU (multivariate logrank test P = 5.06E-36), with EP1 (EP6) having the highest (lowest) chance of not being admitted to ICU (or die prior to that) 91 92 in a 40-day span since their admission to the hospital (Figure 2B). A similar pattern can be 93 observed when patients that died before admission to ICU were excluded (Figure S4, multivariate 94 logrank test P = 6.55E-36). A two-sided Mann-Whitney U (MWU) test showed that patients in EP5 95 were generally older than other EPs (FDR = 6.94E-5), while EP3 included younger patients (FDR = 96 1.82E-4). However, EP6 (which had the most severe patients) did not show enrichment in older 97 patients or individuals with high BMI (two-sided MWU FDR>0.05) (Figure 2C, Table S1).

98

99 These analyses revealed that the unsupervised approach was able to identify endophenotypes 100 with distinct disease characteristics and outcomes using the circulating proteome of the patients. 101 We identified EP6 as a group of participants with an increase in many measures of COVID-19 102 disease severity.

103

104 EP6 is enriched with BQC19's participants having acute respiratory distress syndromes

In accordance with increase disease severity, EP6 was also enriched in COVID-19 medical
 complications (two-sided Fisher's exact test): acute respiratory distress syndrome (ARDS) (FDR =

107 1.43E-10), acute kidney injury (FDR = 6.37E-7), bacterial pneumonia (FDR=2.13E-6), liver 108 dysfunction (FDR = 9.32E-3), and hyperglycemia (FDR = 1.56E-2) (Figure 3, Table S2). The 109 frequency of ARDS was just below 8% in EP1 compared to greater than 44% in EP6, making this 110 complication a key feature of this cluster (Figure 3, Table S2). 111 EP6 is enriched in blood metabolites associated with severe COVID-19. 112 113 To further characterize each EP and gain insight into mechanisms of disease, metabolomic 114 profiling of plasma samples was done in parallel to the SOMAmer analysis. The results yielded 115 data on 1,435 metabolites, of which 576 were found significantly altered in EP6 (two-sided MWU 116 FDR < 0.01). Moreover, the metabolomic characterization of the plasma samples supported the 117 distinction in blood composition at the levels of metabolomic sub-pathways and individual 118 metabolites between the different EPs (Figure 4 and S3). 119 120 Pathway enrichment analysis identifies FGFR-signaling in severe COVID-19 acute respiratory 121 distress syndrome To gain insight into the molecular mechanisms underlying the severity in EP6, we performed 122 123 pathway enrichment analysis using the Knowledge Engine for Genomics (KnowEnG)⁶ for the 124 aptamers associated with EP6. Since aptamers were used to identify the EPs, it is expected that 125 many of them would be significantly associated with the EPs. As a result, we selected a very strict 126 threshold of FDR < 10E-20 (two-sided MWU test) to identify top aptamers associated with EP6 127 (Table S4). We then used the gene set characterization pipeline of KnowEnG with Reactome ¹⁵ 128 pathway collection. This analysis showed that while EP6 is characterized by pathways associated

129	with Interleukins and Cytokine Signaling in Immune system, multiple instances linked it with
130	Fibroblast Growth Factor Receptor (FGFR) signaling, identifying this pathway as a potential driver
131	of severe pathology that was not present in other EPs (Tables 2 and S4).

132

133 SHC4 genotype and protein expression levels are associated with higher odds of belonging to

134 EP6

135 To further improve our understanding of the molecular mechanisms underlying EP6, we 136 leveraged an additional dataset of Genome Wide association Study (GWAS) corresponding to 137 these patients. We identified 25 single nucleotide variations (SNVs) distributed in 13 annotated 138 genes, that were below a p-value threshold of 1E-4 differentiating EP6 versus the rest (Table 3). 139 We then investigated each of the SNVs to which we could assign a gene and an aptamer, to assess 140 whether their protein product in circulation was differentially regulated by the genotype (Table 141 4). We discovered two genes, SHC4 (encoding SHC adaptor protein 4) and CACNA2D3 (encoding 142 calcium voltage-gated channel auxiliary subunit alpha2 delta3) for which there was a significant 143 association between genotype and protein expression levels (p-values < 0.05). While CACNA2D3 144 may have mild impact on EP6 membership (odd ratio = 0.61, Table 4), SHC4 was one of the top-145 enriched aptamers (position 32 out of 4,985), with odds ratio of 11.98 and 2.00 for the protein 146 product and SNV, respectively of belonging to EP6 for the alternative allele. Therefore, the GWAS 147 analysis revealed that the signaling adaptor protein SHC4 may play an important mechanistic role 148 in contributing to severe disease pathology.

149

150 A predictive model based on blood markers predicts EPs in a separate validation cohort

151 To further characterize each EP, we assessed the clinical laboratory results obtained from blood 152 draws and compared them between the groups. We focused on 21 markers that were measured 153 in at least 50% of the patients used for consensus clustering (Figure 5A and Table S5) and used 154 the summary value reported in the BQC19 database corresponding to the most extreme 155 measurement among multiple blood draws (Table S5 provides this information for each blood 156 marker). Figure 5A shows the elevation and depletion of these markers in the identified EPs. EP6 157 is characterized by abnormal values in markers of inflammation (lymphopenia, total white blood 158 cells count, neutrophilia, C-reactive protein (CRP)), liver damage (alanine aminotransferase (ALT), 159 albumin, lactate deshydrogenase (LDH)), blood clotting disorder (D-dimers, low hemoglobin, 160 International Normalized Ratio (INR) and hyperglycemia (glucose).

161

162 To identify relationships that may shed light on factors influencing clinical laboratory results 163 defining EP6, we also performed Spearman's rank correlation analyses between each blood test 164 values and metabolites (Table S5).

165

Since EPs and particularly EP6, which we identified as the EP with worst outcome, showed a clear and distinct clinical laboratory result signature compared to other EPs, we sought to develop a predictive model based on these signatures. Due to the large number of missing values for these markers in our cohort, we developed a nearest-centroid classifier that is capable of dealing with missing values and can predict EPs based on blood markers (see Methods for details). To test the ability of this model on prediction of EPs on an independent yet similar dataset, we used data corresponding to 631 SARS-CoV-2 positive hospitalized BQC19's participants that did not have

circulating proteome data and hence were not used to identify the endophenotypes. The clinical
and pathological characteristics of patients in each predicted endophenotype (PEP) is provided
in Figure 5B-5E and Table S6.

176

177	Our predictive model identified 116 of these patients to belong to EP6. Fisher's exact test showed
178	a significant enrichment of the predicted EP6 (PEP6) in severity/dead (FDR = 1.77E-22), while
179	PEP1 and PEP2 were significantly depleted in these outcomes (FDR = 1.61E-4 and FDR = 1.30E-8,
180	respectively), as shown in Figure 5B and Table S6. Similar to EP6, PEP6 was also significantly
181	enriched in participants 1) receiving oxygen therapy (FDR = 2.38E-8), 2) receiving ventilatory
182	support (FDR = 4.40E-8), and 3) being admitted to ICU (FDR = 1.23E-24) (Table S6). Kaplan Meier
183	analysis also confirmed that these PEPs have a distinct temporal pattern of admission to ICU
184	(multivariate logrank test $P = 1.05E-34$), with PEP6 having the lowest chance of not being
185	admitted to ICU (or die prior to that) in a 40-day span since their admission to the hospital (Figure
186	5E).

187

These results suggest that our predictive model can use these 21 blood markers to generalize the
definition of endophenotypes to patients for whom the proteome data is unavailable.

190

191 Discussion

192 The results presented herein came from a large cohort of deeply phenotyped SARS-CoV-2 193 positive hospitalized participants, combined with unsupervised clustering that provided both 194 expected and novel findings into the molecular mechanisms regulating COVID-19 outcomes.

195 They led to the identification of an endophenotype (EP6) associated with worst clinical outcome 196 of COVID-19 (enriched in acute respiratory distress syndrome) reflected by a greater proportion 197 of ICU admission, mechanical ventilation, and severe/death outcomes (Figure 1). Clinical features 198 of this endophenotype were consistent with published literature with increased levels of CRP, D-199 dimers, elevated neutrophils, and depleted lymphocytes (Figure 5A, Table S5). Our approach 200 enabled the identification of interleukins, FGFR and SHC4 signaling as cardinal features of the 201 molecular pathways associated with severe COVID-19. Importantly, this information was 202 sufficient to train an accurate predictive model that could in the future support clinical care.

203

204 The approach: unsupervised clustering capacity at identifying clinically meaningful 205 subpopulations

206 Our unsupervised clustering approach in conjunction with a rich molecular dataset enabled us to 207 identify endophenotypes that could not be captured using traditional methods classifying the 208 population in two bins solely based on severity. This is in part because of the «many-one» 209 limitation: the same higher-level phenomenon (COVID-19 severity) can be produced by several 210 different molecular mechanisms. Determining endophenotypes using an unsupervised method 211 provides a higher granularity and increases the chance to identify distinct molecular mechanisms 212 and pathways resulting in similar COVID-19 severity. Accordingly, we identified two 213 endophenotypes with more favorable outcomes (EP1 and EP2), three endophenotypes with intermediate outcomes in terms of severity (EP3, EP4 and EP5) and one endophenotype which 214 215 led to worst outcomes compared to all others (EP6).

216

217 The identification of endophenotypes was done systematically using robust consensus clustering 218 of aptamer expression levels in which the optimum number of clusters was determined 219 congruently using two well-established measures: AIC and BIC. The consensus clustering using 220 bootstrap sampling (1000 times) ensured identification of robust clusters that are not sensitive 221 to exclusion of some of the samples (20% randomly selected and excluded at each cycle). 222 Moreover, identifying the best number of clusters using AIC/BIC (both of which agreed with each 223 other) allowed us to reveal the patterns of the EPs directly from the data, instead of imposing a 224 pattern onto it through human supervision. This is an important strength of the study that 225 enabled us to identify distinct molecular patterns of patients that could have remained 226 undetected using other traditional approaches.

227

Moreover, to improve the translational applicability of EPs, we developed a predictive model based only on laboratory measured blood markers to generalize the definition of these endophenotypes to unseen samples without measured aptamer expression levels. Characteristics of EPs predicted solely based on their blood markers were consistent with the original EPs, suggesting the use of blood markers as surrogates for generalizing these EPs to new patients and automating identification of high-risk groups in the clinic.

234

235 COVID-19 molecular pathology

The datasets used in this study carry rich molecular information on mechanisms of disease. SARS-CoV-2 infection has been shown to be associated with altered kynurenin levels associated with increase IL-6 and kidney injury¹⁶. Interestingly, we also observed Kynurenin to be enriched in EP6

but depleted in EP1, supporting the association of increase kynurenin with COVID-19 severity and
the enrichment in acute kidney injury complication.

241

242 Spermidine/spermine N(1)-acetyltransferase (SSAT) contributes to polyamine synthesis. In 243 addition, its extracellular metabolite, N1,N12-diacetylspermine, is one of the top 15 metabolites 244 enriched in EP6 (Figure 4A), is positively correlated with Urea and creatinine, and is negatively 245 correlated with lymphocyte numbers (Table S5). Deletion of SSAT in mice is protective against 246 LPS-induced kidney injury¹⁷. SSAT activity is associated with white blood cell count in Acute Myeloid Leukemia and Chronic Myeloid Leukemia patients¹⁸. This suggest that the tryptophan 247 248 and polyamine metabolisms are associated with acute kidney injury in COVID-19 and identifies 249 potential pathways of disease progression.

250

251 COVID-19 ARDS

252 EP6 is characterized by its enrichment in ARDS (44% vs 8% in EP1, Figure 3). Low levels of 253 Sphingosine 1-phosphate (S1P) are associated with ARDS and were shown to be associated with 254 greater ICU admission and decrease survival in COVID-19¹⁹. Accordingly, we found that S1P levels 255 are depleted in EP6 while they are enriched in EP1 (Figure 4A). Interestingly, the aptamers 256 detecting neutral ceramidase, an enzyme converting ceramides into sphingosine, is enriched in 257 EP1 (although changes in protein abundance as detected by aptamers may not necessarily reflect changes in enzymatic activity). Accordingly, dihydroceramides and ceramides are depleted in 258 259 cluster EP1. Conversely, dihydroceramides and ceramides are significantly enriched in EP6, 260 suggesting that there is a shunting of the pathway away from sphingosine towards more proinflammatory ceramides in EP6 associated with metabolic disorders²⁰. Moreover, one of the top aptamers found enriched in EP6, is the enzyme Serine palmitoyltransferase 2 (SPTLC2) (Table S4)^{21,22};;;;). These results suggest a counterbalance between ceramides and sphingosine, where the former is associated with poorer outcomes during critical illness, whereas higher levels of the latter has more favorable outcomes in ARDS.

266

267 Metabolomic profile of EP6 supports a role for immuno-thrombosis-mediated organ damage in
 268 COVID-19

269 To obtain a more comprehensive understanding of the alteration in metabolic profiles in EP6, we 270 investigated which metabolic subpathways were significantly enriched in EP6 (Figure 4, Table S3). 271 The two top pathways (FDR < 1E-2) are "Methionine, Cysteine, SAM and Taurine Metabolism" 272 and "phosphatidinylethanolamine (PE)". Interestingly, these two pathways are known to 273 interact²³, with PE methylation a major consumer of S-Adenosylmethionine (SAM) leading to the synthesis of S-Adenosylhomocysteine (SAH) and cystathionine²⁴, which itself has been found 274 275 upstream of 2-hydroxybutyrate and 2-aminobutyrate in a model of hepatoxicity²⁵. SAH, 276 cysthathionine, 2-hydroxybutyrate and 2-aminobutyrate are significantly enriched in EP6. 277 Congruently, EP6 is enriched (FDR < 1E-2) in liver dysfunction (Figure 3, Table S2), with markers 278 of liver dysfunction all significantly altered in clinical blood works: ALT, albumin, bilirubin and LDH 279 (Figure 5A, Table S5).

280

PEs become exposed at the surface of cell membranes upon exposure to stress, inflammation,
 and cell death^{26,27}. In a Syrian hamster model, infection with SARS-CoV-2 had markedly increased

283 PE expression in the animals that were fed a high salt, high fat diet, demonstrating the interaction 284 between infection and metabolic disorder with the abundance of circulating PE²⁸. Phospholipids-285 containing microparticles from platelet activation contribute to Tissue Factor activation and prothrombinase activity²⁹. Platelets-derived microparticles have a much greater procoagulant 286 activity than activated platelets³⁰. Exposure of glycerophospholipids in conjunction with 287 phosphatidinylserine (PS) enhances factor X activation and increases pro-thrombinase 288 289 activities^{31,32}. Interestingly, red blood cells exposed to paclitaxel, PS were exposed to the surface by protein kinase C (PKC) zeta activation of scramblase³³. The aptamer detecting PKC zeta is one 290 291 of the top aptamers associated with EP6 (Table S4). PKC zeta can be activated by testosterone, Dehydroepiandrosterone(DHEA)³⁴ and dexamethasone³⁵, signals of relevance to EP6. The 292 293 membranes of azurophilic granules, which contains Cathepsin G representing the most enriched 294 aptamer in EP6, are enriched in PE relative to PC³⁶. Accordingly, EP6 in addition to significantly 295 enhanced PE abundance, showed decrease platelets count, increased D-Dimers, INR and activated partial thromboplastin time (APTT) (Figure 5A, Table S5), hallmarks of Disseminated 296 Intravascular Coagulation (DIC), a serious and often lethal complication of sepsis³⁷. Liver lesions 297 are frequently observed in DIC³⁸, where liver damage can cause DIC, or exacerbate its 298 299 manifestation due to its function in clearing activated products of the coagulation cascade. Taken 300 together, the metabolomic profile of EP6 supports pro-coagulation activity in circulation that can 301 be linked to organ damage.

302

303 Many early reports suggested a role for immunothrombosis involving neutrophil-mediated 304 release of NETs contributing to endothelial dysfunction as a mechanism of microthrombosis in

COVID-19 associated ARDS³⁹⁻⁴¹. These findings have been supported by several studies carried 305 306 out in humans⁴²⁻⁵⁰. All of these studies were performed with 7 to 77 participants. Our study 307 supports these findings in two important ways: 1) we used a much greater sample size (n = 731) 308 and, 2) the identification of molecular factors associated with immuno-thrombosis emerged from 309 an *unsupervised* analysis of deep phenotyping of the participant population. The strength of the 310 extensive characterization performed in this study has enabled the finer definition of molecular mechanisms of disease by providing associations between the circulating proteome, 311 312 metabolome and clinical laboratories results.

313

314 FGFR and SHC4 intracellular signaling in COVID-19 ARDS

315 Two of the outstanding novel molecular factors identified by our study associated with COVID-316 19 ARDS are FGFR and SHC4. Circulating levels of the pro-angiogenic FGF-2 has been associated 317 with COVID-19 severity and creatine levels in a study of 208 SARS-CoV-2 positive participants⁵¹. 318 It is noteworthy that the use of Nintedanib, an inhibitor of FGFR, Vascular Endothelial Growth 319 Factor Receptor (VEGFR) and Platelet-Derived Growth Factor Receptor (PDGF-R) approved for 320 use in interstitial lung disease, improved pulmonary inflammation and helped wean off 321 mechanical ventilation of three middle-aged obese COVID-19 patients where lung function 322 restoration has been challenging⁵². While the adaptor protein SHC4 has not been experimentally 323 demonstrated to modulate FGFR signaling, a 12-gene biomarker signature associated with melanoma contains FGFR2, FGFR3 and SHC4⁵³. In view of the limited knowledge of this 324 325 understudied member of the SHC family, it is attractive to speculate that it may act downstream of FGFR or other associated growth factor receptors linked to angiogenesis, favoring 326

immunothrombosis associated with COVID-19 ARDS. Additional experimentation is required to establish a sound scientific basis for these hypotheses. Moreover, the identity of the cells expressing SHC4, leading to its presence in the circulation is not known, also the focus of ongoing investigations. Taken together, our identification of FGFR and SHC4 signaling pathways distinguishing EP6 from other endophenotypes, supports further investigation of antagonists of those pathways to treat severe lung manifestations of COVID-19 and their potential use as biomarkers of severe disease activity.

334

335 Limitations and considerations

The data presented in this study come from individuals participating to BQC19, a prospective 336 337 observational cohort built to study COVID-19 in Québec (Canada) with its specific population 338 profile as reported previously¹⁰. While the number of participants was sufficient to establish the 339 endophenotypes using the extensive proteomic profile available in BQC19, it was insufficient for 340 traditional genome-wide association study (GWAS) to identify relations between SNVs and the identified endophenotypes⁵⁴. Instead, we exploited the top SNVs that distinguished EP6 from 341 other EPs in a pQTL analysis. Because these results show a potential genetic functional causality, 342 343 it gives us the confidence that these associations are likely not due to random chance; however, 344 the robustness of this approach needs to be further tested in other studies. A chronological bias 345 may also be present, as most of the participants used for endophenotyping in this study were recruited during the first two waves of the pandemic (Figure S1), prior to widespread vaccination 346 347 in Québec and prior to the appearance of the Omicron variant and sub-variants. Therefore, some 348 of the features of the identified endophenotypes may change over the course of the pandemic.

349 It will be essential to continue to assess the molecular profiles longitudinally to better understand 350 the dynamic nature of host-pathogen interactions. It will also be interesting to compare the 351 profiles of COVID-19 ARDS to other viral-induced ARDS, to identify commonalities as well as 352 distinguishing features.

353

354 In this study, we used circulating proteome as determined by aptamers to identify 355 endophenotypes, a task for which it is well suited as it can capture a dynamic landscape. 356 However, several important considerations need to be mentioned. First, raw (unnormalized) 357 expression values of the same aptamer can be used to compare different samples, but these 358 values cannot be used to compare different aptamers against each other in the same sample, 359 since they only show the relative abundance of expression and not absolute expression. As such, 360 one needs to first normalize these values across samples (one aptamer at a time) and then 361 subject them to follow-up analysis such as clustering, an approach that we adopted in this study. 362 Second, since information only shows relative abundance, focusing on an individual aptamer and 363 analyzing it will require additional measurements to establish absolute abundance. Moreover, if 364 one wants to analyze aptamers individually (instead of the collective approach that we used in 365 this study), they need to consider the effect of complexes and non-specific binding that may 366 result in noisy data. As such, we suggest that the aptamer expression data be used collectively 367 and after proper normalization, which enabled us to identify various EPs and important molecular mechanisms discussed in this study. 368

370 In this work, we developed a predictive model based on blood markers that enables us to 371 generalize the definition of EPs to scenarios where data on circulating proteome is not available. 372 This significantly increases the applicability of this approach and may enable automating 373 identification of high-risk individuals in the clinic. However, time and follow-up studies are 374 required to move this predictive model and the definitions of EPs from research to clinic and 375 develop it as an acceptable clinical practice. Nonetheless, our approach can be used to study 376 COVID-19 in different cohorts and identify characteristics that can guide the treatment of the 377 disease.

378

379 Future directions

380 There is enormous amount of data within this study and BQC19 that can and should be exploited 381 by the scientific and medical community to improve our understating of COVID-19 and novel 382 emerging acute respiratory illnesses. Analyzing in more details the molecular profiles of the other 383 EPs, in particular EP3-5, which lead to similar outcomes from distinct molecular pathways should 384 further yield important insights into mechanisms of the disease. For example, EP5 is enriched in males and cardiovascular disease complications, while EP4 is enriched in female (like EP1) but 385 386 with different distinct clinical trajectories pointing to sex-dependent and independent molecular 387 mechanisms of disease.

388

389 Conclusion

The major strength of this study is its starting point: unsupervised analysis of a large and deeplyphenotyped cohort. We showed that this approach can address both fundamental scientific

questions pertaining to mechanisms of disease and help the medical community improve patient
 outcomes through early identification of patient that may follow a severe clinical course during
 COVID-19.

395

396 Methods:

397 Datasets and preprocessing

The Biobanque québécoise de la COVID-19 (BQC19; www.guebeccovidbiobank.ca) is aimed at 398 coordinating the collection of patients' data and samples for COVID-19 related research. Data 399 400 and samples were collected from ten sites across the province of Québec (Canada)¹⁰. BQC19 401 organizes the collected data, including clinical information and multi-omics experimental data, 402 before making it available in successive releases. For this study, we used release #5 of the clinical 403 data published in December 2021, the circulating proteome determined using SOMAmers⁵⁴ and 404 Metabolomics data⁵⁵. BQC19 GWAS imputation data was generated by Tomoko Nakanishi at 405 Brent Richards lab, Jewish General Hospital and McGill University. Detailed codes used for 406 generating the data can be found in: https://github.com/richardslab/BQC19 genotype pipeline 407

Our main corpus of analysis consisted of n = 1,362 hospitalized and SARS-CoV-2 positive patients (based on qRT-PCR) of BQC19. This included n = 731 patients for which both clinical and proteomic data were available as well as n = 631 patients for which proteomic data was not available, but their clinical data contained measurements for more than half (at least 11 out of 21) of the blood markers that we used as a validation set for the predictive model developed in this study.

414

415 We also obtained data (n = 731) corresponding to the circulating proteome measured between 416 April 2, 2020 and April 20, 2021 by a multiplex SOMAmer affinity array (Somalogic, 4,985 417 aptamers) from BQC19 (release #3 Sep. 2021, associated patients' data updated in release #5 418 Dec. 2021). When measurements of the same patients but at different time points were 419 available, we used the one corresponding to the first time point. SomaScan is a biotechnological 420 protocol commercialized by the Somalogic company. It relies on a set of artificial aptamers linked 421 to a fluorophore and each designed to bind a single protein. Once added to the sample, the 422 activity of each aptamer is measured through fluorescence and used to approximate the expression level of the targeted protein. SomaScan protocol comprises several levels of 423 calibration and normalization to correct technical biases¹¹. Log2 and Z-score normalization were 424 425 performed on each aptamer separately in addition to the manufacturer's provided normalized 426 data (hybridization control normalization, intraplate median signal normalization, and median 427 signal normalization). Since the data was analyzed by Somalogic in two separate batches, we 428 applied the z-score transformation separately to each batch, to reduce batch effects. These 429 additional transformations ensure that the measured values of different aptamers are 430 comparable and can be used in cluster analysis.

431

We obtained metabolomic data (1,435 metabolites) from BQC19. We used the batch-normalized,
missing values imputed and log-transformed version of the data.

434

435 Analyses of the GWAS dataset

For the GWAS analyses, annotation of SNVs were done using the biomaRt package⁵⁶ from R⁵⁷ and 436 437 all analyses were done using R version 4.1.3. Quality control steps were derived in majority from a 2017 QC tutorial article⁵⁸. At the beginning, we had 867,450 markers and 2,429 samples. We 438 import Plink format data into R using the "read_plink" function from genio package⁵⁹ from R. We 439 440 removed 103,592 non ACGT bi-allelic markers. We calculated the predicted sex by looking at the rate of homozygote markers on chromosome 23. We removed 3,588 markers with call rates < 441 98%, 448,932 monomorphic markers and markers with MAF <0.05, and 28,092 markers with 442 Hardy Weinberg equilibrium < 1E-6 (calculated by the "HWE.exact" function from the genetics 443 package⁶⁰ from R. For the EP6 cluster group analyses, we removed in addition 1,747 samples that 444 were not in the cluster analysis, 8 samples with a sex discrepancy (based on predicted sex 445 446 calculated earlier and reported sex), and 3 samples with a heterozygosity rate > 3 standard 447 deviations. We finally removed a pair of samples who had approximately the same genome 448 probably due to an error of manipulation. We couldn't know which one was the right sample, so we removed both of them. We also had 2 pairs of individuals who had a pi-hat of ~0.5 (meaning 449 450 first degree relatives), we decided to keep one sample per pair, the one with the higher call rate. 451 All other pairs of individuals had a pi-hat < 0.21 that is judge acceptable considering our 452 population. Pi-hat were calculated with the "snpgdsIBDMoM" function from SNPRelate package⁶¹ from R. At the end of quality controls, 283,246 markers on 655 samples have been 453 454 used to perform association analyses.

455

456 To perform the principal component analyses (PCA), we took a subsample of independent 457 markers (pruning) with a maximum sliding window of 500,000 base pairs and a linkage

disequilibrium (LD) threshold of 0.2 using the "snpgdsLDpruning" function from the SNPRelate
package from R. We ran the PCA with the "snpgdsPCA" function from SNPRelate package from
R. The first 2 principal components (PCs) were considered significant.

461

462 For the GWAS analyses of the 283,246 remaining markers between EP6 cluster compared to all 463 others, we modeled a logistic regression with the dichotomous variable indicating if the 464 participants belong to the EP6 cluster as the outcome variable. We used the additive model for 465 markers as an independent variable and we adjusted the models with the first two PCs. Odds 466 ratio and p-values were calculated on each model. QQ-plots have been performed as quality control of the models; p-values were plotted using "gqplot.pvalues" function from gaston 467 468 package⁶² from R (data not shown). We compared the aptamers' normalized level of expression 469 (based on normalization described earlier) between the three groups of genotypes for each 470 studied genes by performing standard ANOVA analyses followed by Tukey post hoc tests 471 (referred to in this study as pQTL analysis). Since aptamers tested are limited compared to the 472 SNVs, we have fixed significance p-values threshold below 1E-4 to report more SNVs instead of 473 the more common 1E-5 suggestive threshold. Finally, to identify if the cluster EP6 may be 474 explained by the aptamers and the SNVs, we performed multiple logistic regression analyses models include aptamers expression values, SNV genotypes (additive model) and the two 475 476 principal components. OR are reported with 95% confidence intervals.

477

478 **Consensus agglomerative clustering**

Patients were clustered using agglomerative clustering, with Euclidean distance and Ward's linkage^{12,13}. To identify number of clusters k, we used the elbow method based on the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). More specifically, we calculated the AIC and BIC for clustering using k = 2, 3, ..., 20 and used the Kneedle algorithm⁶³ to identify the value of k corresponding to the "elbow", where increasing the value of k does not provide much better modeling of the data. Kneedle identified k = 6 as the number of clusters based on both AIC and BIC (Figure 1A).

486

Given the number of clusters in the data, we then used consensus clustering with sub-sampling 487 488 to obtain robust endophenotypes. We randomly sampled 80% of the patients 1000 times. Each 489 time, we used agglomerative clustering above with k = 6 to identify clusters. Given these 1000 490 clusterings, we calculated the frequency of two patients appearing in the same cluster, when 491 both were present in the randomly formed dataset. We then performed one final agglomerative 492 clustering of these frequency scores to identify the six endophenotypes (Figure S2A and Figure 493 1B). The distribution of Rand-Index, showing the concordance between each one of the 1000 clusterings and the final consensus clustering is provided in Figure S2B (mean Rand-Index = 494 495 0.823), reflecting a high degree of consistency.

496

497 Metabolomic pathway characterization of EP6

The 1435 metabolites measured were organized into 122 sub-pathways in the original dataset (denoted as "SUB_PATHWAYS"). We first identified metabolites whose values were significantly higher or lower in EP6 compared to other EPs (two-sided MWU test, FDR<0.01). Then, we used

501 these metabolites to perform pathway enrichment analysis (one-sided Fisher's exact test) based 502 on 122 pathways. The resulting p-values (Table S3) were then corrected for multiple tests using 503 Benjamini-Hochberg FDR.

504

505 Nearest-centroid predictor based on blood markers

506 In order to predict endophenotypes from blood tests, we developed a missing-value resilient 507 nearest-centroid classifier. We used the set of patients that were used to form the original EPs 508 (n = 731) as the training set and the set of patients that did not have proteome data as the validation set (n = 631). First, we z-score normalized each blood marker across all the patients in 509 510 the training set, one marker at a time. We then formed a blood marker signature (a vector of 511 length 21) for each EP. Each element of an EP's signature corresponds to the mean of the 512 corresponding marker across all patients of that EP.

513

514 To predict the EP label of each patient in the test set, we first z-score normalized their blood 515 marker measurements using the mean and standard deviation of the blood markers calculated 516 from the training set. Then, we calculated the cosine distance between each test patient's blood 517 marker profile and the centroids (excluding missing values) and identified the nearest EP as the 518 predicted EP (PEP) label of the patient.

519

520 Acknowledgements

521 This work was made possible through open sharing of data and samples from the Biobanque 522 québécoise de la COVID-19, funded by the Fonds de recherche du Québec - Santé, Génome

Québec, the Public Health Agency of Canada and, as of March 2022, the Ministère de la Santé et
des Services Sociaux du Québec. We thank all participants to BQC19 for their contribution. This
study was supported by the Fonds de recherche du Québec - Santé (FRQS)- Cardiometabolic
Health, Diabetes and Obesity Research Network (CMDO)- Initiative. This work was also supported
by Natural Sciences and Engineering Research Council of Canada (NSERC) grant RGPIN-201904460 (AE).

529

530 Permissions

The study was approved by the Institutional Ethics Review Board of the "Centre intégré
universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean" (CIUSSS-SLSJ) affiliated
to Université de Sherbrooke [protocol #2021-369, 2021-014 CMDO – COVID19].

534 Figures



- 536 **Figure 1:** Unsupervised consensus clustering of SARS-CoV-2 positive patients.
- 537 A) The elbow points (circles in red) of Akaike's Information Criteria (AIC) and Bayesian 538 Information Criteria (BIC) curves versus number of clusters consistently corresponded to k=6 as
- the optimal number of clusters. B) The heatmap shows the expression of aptamers (rows) in each
- 540 sample (columns). The dendogram shows the identified endophenotypes. C) Characterization of
- 541 samples based on sex at birth, highest world health organization (WHO) severity level achieved,
- 542 intensive care unit (ICU) admission, ventilatory support, and oxygen therapy. For the last three
- 543 rows, a sample colored "black" reflects a label of "yes".



544



546 A) Enrichment or depletion of each EP in clinical variables (one cluster versus rest). Two-sided 547 Fisher's exact tests are used to calculate the p-values, which are corrected for multiple tests using Benjamini-Hochberg false discovery rate (FDR). Gradients of blue show depletion, while gradients 548 of red show enrichment. FDR values above 0.05 are depicted as white. B) The number of patients 549 550 in each EP and the colors used to represent them in panels C, D, and E. C) Kaplan-Meier analysis 551 of the time between patients' admission to the hospital and their admission to intensive care unit 552 (ICU) (or death if earlier) for each EP (Delta). D) Distribution of age in each EP. E) Distribution of BMI in each EP. F) COVID-19 severity in each EP. 553

		Anemia: Yes	20%	18%	15%	21%	42%	26%
		Bacteremia: Yes	2%	2%	3%	8%	14%	11%
FUI	JO-2	Bronchiolitis: Yes	- 0%	0%	1%	0%	0%	0%
	- 10 -	Seizure: Yes	- 0%	2%	1%	0%	0%	1%
	- 10 ⁻⁴	Liver dysfunction: Yes	- 8%	8%	8%	5%	5%	19%
	- 10 ⁻⁶	Pleural effusion: Yes	- 8%	2%	2%	3%	8%	4%
	10	Gastrointestinal haemorrhage: Yes	- 3%	2%	1%	0%	0%	3%
	- 10 ⁻⁸	Hyperglycemia: Yes	12%	11%	11%	17%	20%	25%
	- 10 ⁻¹⁰	Hypoglycemia: Yes	- 5%	2%	1%	3%	2%	3%
		Acute kidney injury: Yes	23%	15%	10%	16%	46%	45%
Meningitis or encephalitis: Yes -				0%	0%	0%	0%	3%
		Pancreatitis: Yes	- 1%	0%	1%	0%	5%	2%
Bacterial pneumonia: Yes -				12%	18%	19%	31%	41%
	Cryptogen	ic organizing pneumonia (COP): Yes	- 0%	0%	0%	0%	0%	1%
		Viral pneumonia/pneumonitis: Yes	47%	32%	23%	43%	46%	37%
		Pneumothorax: Yes	- 1%	1%	0%	3%	0%	3%
		Rhabdomyolysis or myositis: Yes	- 0%	0%	0%	0%	2%	2%
Acute Respiratory Distress Syndrome (ARDS): Yes -				12%	12%	23%	27%	44%
Other complications: Yes -				26%	19%	33%	41%	37%
(Other viral	infection during hospitalization: Yes	2%	2%	0%	1%	2%	2%
Positive bacterial culture during hospitalization: Yes -				12%	8%	13%	25%	24%
			EP1	EP2	EP3	EP4	EP5	EP6

554 **Figure 3:** Frequency and significance of complications in different EPs.

556 The value in each cell shows the percentage of patients of that EP (column) that suffered from

the complication (row). The colors represent two-sided Fisher's exact test false discovery rate

558 (FDR, corrected for multiple tests). Red represents enrichment, while blue represents depletion.

559 FDR values below 0.05 are shown as white.



560

- 561 **Figure 4:** Metabolite characteristics of endophenotypes (EPs).
- A) The heatmap shows the over-expression (red) and under-expression (blue) of metabolites in
- different EPs (two-sided Mann–Whitney U test). Row names show metabolites followed by the
- sub-pathway to which they belong in parentheses. Only top 15 metabolites (based on false
- discovery rate for EP6) for which a definite name and sub-pathway was available are shown. Full
- 566 list is provided in Table S3. B) The heatmap shows the enrichment (one-sided Fisher's exact test)
- 567 of EPs in differen

576 500 - 522 500 - 522 500 - 522 500 - 229 500 - 229 100 - 131 e Table S3 for the full list.



568

569 **Figure 5:** Differential expression patterns of blood markers in the identified endophenotypes 570 (EPs) and characterization of predicted endophenotypes (PEPs) based on the predictive model.

571 A) Heatmaps of false discovery rates (FDR) values for two-sided one-vs-rest Mann–Whitney U

tests for 21 blood markers for each EP. Abbreviations used: WBC = white blood cells, LDH = lactate

573 deshydrogenase, ALT = alanine aminotransferase, APTT = activated partial thromboplastin time,

574 INR = International Normalized Ratio. FDR values below 0.05 are shown as white. B) World health

575 organization COVID-19 severity assessed in each PEP. C) Distribution of age in each PEP. D)

576 Distribution of BMI in each PEP. E) Kaplan-Meier analysis of the time between patients' admission

577 to the hospital and their admission to ICU (or death if earlier) for each PEP (Delta). The colormap

- 578 in panel E shows the number of patients in each PEP group and the colors used to represent them
- 579 in panels C, D, and E. PEPs were predicted based on blood markers and were not used to originally
- 580 identify the EPs.

581 Tables

		Cohort
		(n = 1,362)
		No. (%)
	<45	17.5
Ago in yoars	45-65	33.6
Age in years	>65	48.7
	Unknown	0.3
	<20	3.8
	20-25	13.0
Body mass	25-35	27.8
index in kg/m-	>35	7.4
	Unknow	47.9
Cov at hirth	Female	44.8
Sex at birth	Male	55.2
	Dead	4.4
Severity	Severe	21.8
	Moderate	51.0
	Mild	11.8
	Unknown	10.9
0	Yes	48.2
Oxygen	No	21.0
therapy	Unknown	30.8
Ventileter	Yes	47.6
ventilatory	No	14.0
support	Unknown	38.5
Admission to	Yes	17.5
intensive care	No	33.6
unit	Unknown	48.7

582 **Table 1:** Clinical and pathological characteristics of the BQC19's participants used in this study.

Table 2: Reactome pathways associated with EP6, based on expression of aptamers. KnowEnG
 analytical platform was used. The p-values were calculated using a one-sided Fisher's exact test
 and were corrected for multiple tests using Benjamini-Hochberg method. Only signaling
 pathways with FDR<5E-4 are shown in this table (see Table S4 for the full list).

588

Pathway	FDR
Signaling by Interleukins	2.75E-12
Cytokine Signaling in Immune system	6.25E-10
Immune System	2.28E-06
Signaling by FGFR	4.75E-06
Constitutive Signaling by Aberrant PI3K in Cancer	2.94E-05
FGFR2 ligand binding and activation	5.77E-05
Extracellular matrix organization	1.85E-04
FGFR3 ligand binding and activation	1.85E-04
FGFR3c ligand binding and activation	1.85E-04
FGFRL1 modulation of FGFR1 signaling	1.85E-04
TNFs bind their physiological receptors	2.58E-04
PI3K/AKT Signaling in Cancer	3.28E-04
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	4.14E-04
Interleukin-4 and 13 signaling	4.91E-04

SNV ID	Position	Gene Symbol	SNV 1	MAF	HWE	OR ²	p-value
rs1394671	chr5:7348567	-	G > A	0.240	0.095	2.28	2.41E-06
rs12186698	chr5:168880668	SLIT3	T > C	0.087	0.247	2.93	3.72E-06
rs11625406	chr14:50049474	-	C > A	0.438	0.137	0.47	1.03E-05
rs11862889	chr16:83828886	-	T > C	0.104	0.446	2.62	1.07E-05
rs2995918	chr4:37905775	TBC1D1	C > T	0.494	0.776	0.49	1.20E-05
rs16897810	chr5:68415296	-	G > A	0.093	0.001	2.67	1.43E-05
rs2376263	chr17:35436659	SLFN13	G > A	0.261	0.073	2.01	2.48E-05
rs4790712	chr17:1614620	SLC43A2	G > A	0.441	0.003	1.97	2.50E-05
rs2294566	chr20:41472939	CHD6	C > A	0.239	0.265	2.04	2.78E-05
rs7164451	chr15:48921859	SHC4	G > A	0.386	0.053	1.89	3.01E-05
rs57664621	chr8:22808443	PEBP4	G > C	0.174	0.016	2.16	3.07E-05
rs28482919	chr3:14903094	FGD5	T > C	0.187	0.053	0.32	3.20E-05
rs6559283	chr9:89712560	-	T > C	0.375	<0.001	1.96	3.27E-05
rs657075	chr5:132094425	-	A > G	0.104	0.328	2.49	4.28E-05
rs56235109	chr15:62424001	TLN2	A > G	0.235	0.366	0.38	4.67E-05
rs7620057	chr3:179473377	GNB4	T > C	0.099	1.000	2.51	4.67E-05
rs10466868	chr12:131455375	-	T > G	0.108	0.401	2.51	5.94E-05
rs2236798	chr1:18735127	PAX7	A > G	0.054	0.114	2.90	6.11E-05
rs3774814	chr4:5464702	STK32B	C > G	0.205	<0.001	0.36	6.75E-05
rs4497815	chr19:22903215	-	G > A	0.216	0.205	2.07	7.52E-05
rs6765694	chr3:54601810	CACNA2D3	G > A	0.404	0.833	0.51	7.66E-05
rs2797773	chr6:37559045	-	C > T	0.422	0.000	0.53	8.06E-05
rs17014760	chr4:129419725	-	A > A	0.316	0.000	1.89	9.33E-05
rs10948260	chr6:45835559	-	G > A	0.366	0.189	1.81	9.52E-05
rs12035677	chr1:232391209	-	A > G	0.063	0.000	3.02	9.95E-05

591	Table 3: SNVs differentiating EP6 against all other endophenotype clusters	5.
-----	--	----

Abbreviations used: SNV = Single nucleotide variation, HWE = Hardy Weinberg Equilibrium, MAF
 = Minor allele frequency, OR = Odd ratio.

594

¹ SNV are described following GWAS annotations: refence allele > alternative allele (e.g., G > A).

² Logistic regression analyses using additive model adjusted for the 2 principal components.

598 **Table 4:** Association between genotypes and aptamer expression levels

	Gene	Aptamers normalized expression ¹			Multiple logistic regression analyses ³					
SNV	Symbol	gene	B HM	Aptamers		SNV				
			·····iei		arc	P	OR	p-val	OR	p-val
			-0.09	0.01	0.24 *	0.014	0.61	2.5E-4	0.52	2.4E-4
rs6765694	CACNA2D3	-	(±0.89)	(±1.10)	(±0.99)	0.011	(0.46-0.79)		(0.37-0.74)	
m10048260		CHEF	0.02	0.02	-0.02	0.796	0.68	1.7E-4	1.83	8.8E-5
1510948260	-	CLICS	(±0.92)	(±1.09)	(±0.97)		(0.55-0.83)		(1.35-2.48)	
mc [707 [-0.01	0.05	0.32	0.328 (1.37	8.2E-4	2.49	5.2E-5
15057075	-	11.3	(±1.01)	(±0.99)	(±0.46)		(1.14-11.64)		(1.60-3.88)	
rc71611E1	SUCA		-0.07	0.01	0.23 *	0.017	11.98	8.4E-	2.00	1.8E-3
15/104451	3864	-	(±0.90)	(±1.05)	(±1.16)	(7.61-18.8	(7.61-18.87)	27	(1.30-3.09)	
rc12196609	51172		0.00	0.07	0.15	0 500	0.82	0 1 2 5	2.99	2 75 6
1512100090	SLITS	-	(±1.02)	(±1.06)	(±0.89)	0.509	(0.64-1.06)	0.155	(1.89-4.73)	Z./E-0
mcC22C100	Ə TLN2		-0.03	0.06	0.04	0 252	0.58	2 75 5	0.38	
1220232109		-	(±0.98)	(±1.03)	(±1.27)	0.353	(0.45-0.75)	2.7E-5	(0.23-0.60)	4./E-5

599 Abbreviations used: SNV = Single nucleotide variation, HM_{ref} = Homozygotes for the reference 600 allele, HM_{alt} = Homozygotes for the alternative allele, HTZ = Heterozygotes, OR = Odd ratio.

601

¹ Aptamers' normalized levels of expression are reported as mean (± standard deviation).
 Normalization steps for aptamer expressions are described in Methods.

² p-value, standard ANOVA analyses followed by Tukey *post hoc* analyses. Asterisks (*) identify
 difference between HM_{ref} and HM_{alt} genotypes.

³ Multiple logistic regression analyses models include aptamers expression values, SNV
 genotypes (additive model) and the two principal components. OR are reported with 95%
 confidence intervals in parentheses.

609 References

- Rubin, R. As their numbers grow, COVID-19 "long haulers" stump experts. Jama 324,
 1381-1383 (2020).
- 612 2 Marshall, J. C. *et al.* A minimal common outcome measure set for COVID-19 clinical 613 research. *The Lancet Infectious Diseases* **20**, e192-e197 (2020).
- Hull, D. L. in *PSA: Proceedings of the biennial meeting of the philosophy of science association.* 653-670 (Cambridge University Press).
- 6164Berrettini, W. H. Genetic bases for endophenotypes in psychiatric disorders. Dialogues617Clin Neurosci 7, 95-101 (2005). https://doi.org/10.31887/DCNS.2005.7.2/wberrettini
- 618 5 Russell, C. D. & Baillie, J. K. Treatable traits and therapeutic targets: goals for systems
 619 biology in infectious disease. *Current opinion in systems biology* 2, 140-146 (2017).
- 6206Blatti III, C. et al. Knowledge-guided analysis of "omics" data using the KnowEnG cloud621platform.PLoSbiology18,e3000583(2020).622https://doi.org/10.1371/journal.pbio.3000583
- Emad, A. *et al.* Superior breast cancer metastasis risk stratification using an epithelial mesenchymal-amoeboid transition gene signature. *Breast Cancer Research* 22, 74 (2020).
 <u>https://doi.org/10.1186/s13058-020-01304-8</u>
- 6268Te Pas, M. F. W., Madsen, O., Calus, M. P. L. & Smits, M. A. The Importance of627Endophenotypes to Evaluate the Relationship between Genotype and External628Phenotype. International Journal of Molecular Sciences 18, 472 (2017).
- 629 Al-Hadrawi, D. S., Al-Rubaye, H. T., Almulla, A. F., Al-Hakeim, H. K. & Maes, M. Lowered 9 630 oxygen saturation and increased body temperature in acute COVID-19 largely predict 631 chronic fatigue syndrome and affective symptoms due to Long COVID: A precision 632 nomothetic approach. Acta Neuropsychiatr, (2022).1-12 633 https://doi.org/10.1017/neu.2022.21
- 63410Tremblay, K. et al. The Biobanque québécoise de la COVID-19 (BQC19)—A cohort to635prospectively study the clinical and biological determinants of COVID-19 clinical636trajectories.PloSone16,e0245031(2021).637https://doi.org/10.1371/journal.pone.0245031
- Gold, L. *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery.
 Nature Precedings, 1-1 (2010).
- 64012Ward Jr, J. H. Hierarchical grouping to optimize an objective function. Journal of the641American statistical association 58, 236-244 (1963).
- Murtagh, F. & Legendre, P. Ward's Hierarchical Agglomerative Clustering Method: Which
 Algorithms Implement Ward's Criterion? *Journal of Classification* **31**, 274-295 (2014).
 <u>https://doi.org/10.1007/s00357-014-9161-z</u>
- Kaplan, E. L. & Meier, P. Nonparametric Estimation from Incomplete Observations. *Journal of the American Statistical Association* 53, 457-481 (1958).
 <u>https://doi.org/10.1080/01621459.1958.10501452</u>
- 648 15 Gillespie, M. *et al.* The reactome pathway knowledgebase 2022. *Nucleic Acids Research*649 50, D687-D692 (2021). <u>https://doi.org/10.1093/nar/gkab1028</u>
- 65016Thomas, T. *et al.* COVID-19 infection alters kynurenine and fatty acid metabolism,651correlating with IL-6 levels and renal status. *JCI insight* 5 (2020).

Zahedi, K. *et al.* The role of spermidine/spermine N 1-acetyltransferase in endotoxininduced acute kidney injury. *American Journal of Physiology-Cell Physiology* 299, C164C174 (2010).

- Pirnes-Karhu, S. *et al.* Spermidine/spermine N1-acetyltransferase activity associates with
 white blood cell count in myeloid leukemias. *Experimental Hematology* 42, 574-580
 (2014).
- 65819Marfia, G. *et al.* Decreased serum level of sphingosine-1-phosphate: a novel predictor of659clinical severity in COVID-19. *EMBO molecular medicine* **13**, e13424 (2021).
- Lachkar, F., Ferré, P., Foufelle, F. & Papaioannou, A. Dihydroceramides: their emerging
 physiological roles and functions in cancer and metabolic diseases. *American Journal of Physiology-Endocrinology and Metabolism* **320**, E122-E130 (2021).
- Lone, M. A. *et al.* Subunit composition of the mammalian serine-palmitoyltransferase
 defines the spectrum of straight and methyl-branched long-chain bases. *Proceedings of the National Academy of Sciences* 117, 15591-15598 (2020).
- Han, G. *et al.* Identification of small subunits of mammalian serine palmitoyltransferase
 that confer distinct acyl-CoA substrate specificities. *Proceedings of the National Academy of Sciences* 106, 8186-8191 (2009).
- Blachier, F., Andriamihaja, M. & Blais, A. Sulfur-Containing Amino Acids and Lipid
 Metabolism. *The Journal of Nutrition* **150**, 2524S-2531S (2020).
 <u>https://doi.org/10.1093/jn/nxaa243</u>
- Ye, C., Sutter, B. M., Wang, Y., Kuang, Z. & Tu, B. P. A metabolic function for phospholipid
 and histone methylation. *Molecular cell* 66, 180-193. e188 (2017).
- Parman, T. *et al.* Toxicogenomics and metabolomics of pentamethylchromanol (PMCol)induced hepatotoxicity. *Toxicological Sciences* **124**, 487-501 (2011).
- 67626Stafford, J. H. & Thorpe, P. E. Increased exposure of phosphatidylethanolamine on the677surface of tumor vascular endothelium. *Neoplasia* **13**, 299-IN292 (2011).
- Ran, S., Downes, A. & Thorpe, P. E. Increased exposure of anionic phospholipids on the
 surface of tumor blood vessels. *Cancer research* 62, 6132-6140 (2002).
- Port, J. R. *et al.* High-fat high-sugar diet-induced changes in the lipid metabolism are
 associated with mildly increased COVID-19 severity and delayed recovery in the Syrian
 hamster. *Viruses* 13, 2506 (2021).
- Ataga, K. I. Hypercoagulability and thrombotic complications in hemolytic anemias. *Haematologica* 94, 1481-1484 (2009). <u>https://doi.org/10.3324/haematol.2009.013672</u>
- Sinauridze, E. I. *et al.* Platelet microparticle membranes have 50-to 100-fold higher
 specific procoagulant activity than activated platelets. *Thrombosis and haemostasis* **97**,
 425-434 (2007).
- 68831Tavoosi, N. et al. Molecular Determinants of Phospholipid Synergy in Blood Clotting *.689Journal of Biological Chemistry286, 23247-23253 (2011).690https://doi.org/10.1074/jbc.M111.251769
- Majumder, R., Liang, X., Quinn-Allen, M. A., Kane, W. H. & Lentz, B. R. Modulation of
 prothrombinase assembly and activity by phosphatidylethanolamine. *Journal of Biological Chemistry* 286, 35535-35542 (2011).
- 69433Kim, K. *et al.* Pro-coagulant and pro-thrombotic effects of paclitaxel mediated by red695blood cells. *Thrombosis and Haemostasis* **118**, 1765-1775 (2018).

- Sato, K., Iemitsu, M., Aizawa, K. & Ajisaka, R. Testosterone and DHEA activate the glucose
 metabolism-related signaling pathway in skeletal muscle. *American Journal of Physiology- Endocrinology and Metabolism* 294, E961-E968 (2008).
- 69935Kajita, K. *et al.* Glucocorticoid-induced insulin resistance associates with activation of700protein kinase C isoforms. *Cellular signalling* **13**, 169-175 (2001).
- MacDonald, J. & Sprecher, H. Distribution of arachidonic acid in choline-and
 ethanolamine-containing phosphoglycerides in subfractionated human neutrophils.
 Journal of Biological Chemistry 264, 17718-17726 (1989).
- 704 37 Papageorgiou, C. *et al.* Disseminated intravascular coagulation: an update on
 705 pathogenesis, diagnosis, and therapeutic strategies. *Clinical and Applied* 706 *Thrombosis/Hemostasis* 24, 8S-28S (2018).
- Esaki, Y., Hirokawa, K., Fukazawa, T. & Matsuda, T. Immunohistochemical study on the
 liver in autopsy cases with disseminated intravascular coagulation (DIC) with reference to
 clinicopathological analysis. *Virchows Archiv A* 404, 229-241 (1984).
- Barnes, B. J. *et al.* Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *Journal of Experimental Medicine* **217** (2020).
- Bonaventura, A. *et al.* Endothelial dysfunction and immunothrombosis as key pathogenic
 mechanisms in COVID-19. *Nature Reviews Immunology* 21, 319-329 (2021).
- Ding, J. *et al.* A network-informed analysis of SARS-CoV-2 and hemophagocytic
 lymphohistiocytosis genes' interactions points to Neutrophil extracellular traps as
 mediators of thrombosis in COVID-19. *PLoS Computational Biology* 17, e1008810 (2021).
 https://doi.org/10.1371/journal.pcbi.1008810
- Blasco, A. *et al.* Assessment of neutrophil extracellular traps in coronary thrombus of a
 case series of patients with COVID-19 and myocardial infarction. *JAMA cardiology* 6, 469474 (2021).
- 72143Desilles, J. P. *et al.* Impact of COVID-19 on thrombus composition and response to722thrombolysis: Insights from a monocentric cohort population of COVID-19 patients with723acute ischemic stroke. Journal of Thrombosis and Haemostasis **20**, 919-928 (2022).
- 72444Englert, H. *et al.* Defective NET clearance contributes to sustained FXII activation in725COVID-19-associated pulmonary thrombo-inflammation. *EBioMedicine* **67**, 103382726(2021).
- 45 Leppkes, M. *et al.* Vascular occlusion by neutrophil extracellular traps in COVID-19.
 EBioMedicine 58, 102925 (2020).
- Middleton, E. A. *et al.* Neutrophil extracellular traps contribute to immunothrombosis in
 COVID-19 acute respiratory distress syndrome. *Blood* 136, 1169-1179 (2020).
- 73147Obermayer, A. et al. Neutrophil extracellular traps in fatal COVID-19-associated lung732injury. Disease markers **2021** (2021).
- Ouwendijk, W. J. *et al.* High levels of neutrophil extracellular traps persist in the lower
 respiratory tract of critically ill patients with coronavirus disease 2019. *The Journal of infectious diseases* 223, 1512-1521 (2021).
- Petito, E. *et al.* Association of neutrophil activation, more than platelet activation, with
 thrombotic complications in coronavirus disease 2019. *The Journal of infectious diseases* **223**, 933-944 (2021).

50 Skendros, P. *et al.* Complement and tissue factor–enriched neutrophil extracellular traps
740 are key drivers in COVID-19 immunothrombosis. *The Journal of clinical investigation* 130,
741 6151-6157 (2020).

- 51 Smadja, D. M. *et al.* Placental growth factor level in plasma predicts COVID-19 severity 343 and in-hospital mortality. *Journal of Thrombosis and Haemostasis* **19**, 1823-1830 (2021).
- 74452Bussolari, C. *et al.* Case Report: Nintedaninb May Accelerate Lung Recovery in Critical745Coronavirus Disease 2019. *Frontiers in Medicine* **8**, 766486 (2021).
- Liu, W., Peng, Y. & Tobin, D. J. A new 12-gene diagnostic biomarker signature of melanoma
 revealed by integrated microarray analysis. *PeerJ* 1, e49 (2013).
 https://doi.org/10.7717/peerj.49
- 749 54 Zhou, S. *et al.* A Neanderthal OAS1 isoform protects individuals of European ancestry
 750 against COVID-19 susceptibility and severity. *Nature Medicine* 27, 659-667 (2021).
 751 <u>https://doi.org/10.1038/s41591-021-01281-1</u>
- Ford, L. *et al.* Precision of a Clinical Metabolomics Profiling Platform for Use in the
 Identification of Inborn Errors of Metabolism. *The Journal of Applied Laboratory Medicine*5, 342-356 (2020). https://doi.org/10.1093/jalm/jfz026
- Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration
 of genomic datasets with the R/Bioconductor package biomaRt. *Nature Protocols* 4, 11841191 (2009). <u>https://doi.org/10.1038/nprot.2009.97</u>
- 75857R Core Team. R: A Language and Environment for Statistical Computing. https://www.R-759project.org/. (R Foundation for Statistical Computing, Vienna, Austria, 2022).
- Marees, A. T. *et al.* A tutorial on conducting genome-wide association studies: Quality
 control and statistical analysis. *Int J Methods Psychiatr Res* 27, e1608 (2018).
 <u>https://doi.org/10.1002/mpr.1608</u>
- 76359Ochoa, A. genio: Genetics Input/Output Functions. R package version 1.1.1.764https://CRAN.R-project.org/package=genio (2022).
- 76560Warnes, G., Gorjanc, G., Leisch, F. & Man, M. genetics: Population Genetics. R package766version 1.3.8.1.3. https://CRAN.R-project.org/package=genetics (2021).
- 767 61 Zheng, X. *et al.* A high-performance computing toolset for relatedness and principal
 768 component analysis of SNP data. *Bioinformatics* 28, 3326-3328 (2012).
 769 <u>https://doi.org/10.1093/bioinformatics/bts606</u>
- Perdry, H. & Dandine-Roulland, C. gaston: Genetic Data Handling (QC, GRM, LD, PCA) &
 Linear Mixed Models. R package version 1.5.7. <u>https://CRAN.R-</u>
 project.org/package=gaston (2020).
- Satopaa, V., Albrecht, J., Irwin, D. & Raghavan, B. in 2011 31st international conference on
 distributed computing systems workshops. 166-171 (IEEE).
- 775